Pain and Inflammation Research

Although separate conditions, pain and inflammation are nearly always associated with each other. Pain is defined by the International Association for the Study of Pain (IASP) as 'an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage'. Inflammation is the tissue's immunologic response to injury, characterized by mobilization of white blood cells and antibodies, swelling, and fluid accumulation.

Pain and Inflammation Research Products Areas

Products for Pain and Inflammation Research - Page 45

Cat.No. Product Name Information/Activity
BCC7075 AACOCF3 Phospholipase A<sub>2</sub> inhibitor
BCC1509 D609 D609 is a selective competitive inhibitor of phosphatidyl choline-specific phospholipase C (PC-PLC), with Ki of 6.4 μM.
BCC7537 Edelfosine 77286-66-9
BCC7721 FIPI FIPI is a derivative of halopemide which potently inhibits both PLD1 and PLD2 with IC50s of 25 nM and 20 nM, respectively.
BCC7728 LY 311727 164083-84-5
BCC2310 Varespladib (LY315920) Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively.
BCC6716 OBAA 221632-26-4
BCC7074 PACOCF3 Phospholipase A<sub>2</sub> inhibitor
BCC8083 RHC 80267 RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC50 of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC50 of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC).
BCC5199 U-73122 U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50of 1-2.1 µM for PLC.